JP2002316927A - Composition for common cold - Google Patents
Composition for common coldInfo
- Publication number
- JP2002316927A JP2002316927A JP2001120419A JP2001120419A JP2002316927A JP 2002316927 A JP2002316927 A JP 2002316927A JP 2001120419 A JP2001120419 A JP 2001120419A JP 2001120419 A JP2001120419 A JP 2001120419A JP 2002316927 A JP2002316927 A JP 2002316927A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- common cold
- symptoms
- cough
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- 201000009240 nasopharyngitis Diseases 0.000 title abstract description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims abstract description 10
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims abstract description 10
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims abstract description 7
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960000991 ketoprofen Drugs 0.000 claims abstract description 7
- 229960002009 naproxen Drugs 0.000 claims abstract description 7
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims abstract description 7
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960001680 ibuprofen Drugs 0.000 claims abstract description 6
- 229960002373 loxoprofen Drugs 0.000 claims abstract description 6
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 claims abstract description 6
- PXWLVJLKJGVOKE-UHFFFAOYSA-N propyphenazone Chemical compound O=C1C(C(C)C)=C(C)N(C)N1C1=CC=CC=C1 PXWLVJLKJGVOKE-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960002189 propyphenazone Drugs 0.000 claims abstract description 6
- 229960005489 paracetamol Drugs 0.000 claims abstract description 5
- 229960003908 pseudoephedrine Drugs 0.000 claims abstract description 5
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 13
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 abstract 1
- 206010011224 Cough Diseases 0.000 description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 239000004359 castor oil Substances 0.000 description 5
- 235000019438 castor oil Nutrition 0.000 description 5
- -1 chewables Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 description 5
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 5
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- DBAKFASWICGISY-DASCVMRKSA-N Dexchlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 DBAKFASWICGISY-DASCVMRKSA-N 0.000 description 2
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 2
- 239000000150 Sympathomimetic Substances 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229960002504 capsaicin Drugs 0.000 description 2
- 235000017663 capsaicin Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229960002146 guaifenesin Drugs 0.000 description 2
- 238000011597 hartley guinea pig Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 230000001975 sympathomimetic effect Effects 0.000 description 2
- 229940064707 sympathomimetics Drugs 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- BHMLFPOTZYRDKA-IRXDYDNUSA-N (2s)-2-[(s)-(2-iodophenoxy)-phenylmethyl]morpholine Chemical compound IC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 BHMLFPOTZYRDKA-IRXDYDNUSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- MIBMNQZAMATABQ-UHFFFAOYSA-N [K].C1(=C(O)C(=CC=C1)S(=O)(=O)O)OC Chemical compound [K].C1(=C(O)C(=CC=C1)S(=O)(=O)O)OC MIBMNQZAMATABQ-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000428 carbinoxamine Drugs 0.000 description 1
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 description 1
- 229960000456 carbinoxamine maleate Drugs 0.000 description 1
- GVNWHCVWDRNXAZ-BTJKTKAUSA-N carbinoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 GVNWHCVWDRNXAZ-BTJKTKAUSA-N 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 229960004708 noscapine Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000002976 pectoralis muscle Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- UZXRQGSKGNYWCP-UHFFFAOYSA-M potassium 4-hydroxy-3-methoxybenzenesulfonate hydrate Chemical compound O.[K+].COc1cc(ccc1O)S([O-])(=O)=O UZXRQGSKGNYWCP-UHFFFAOYSA-M 0.000 description 1
- 229940069505 potassium guaiacolsulfonate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000007391 self-medication Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- JWIXXNLOKOAAQT-UHFFFAOYSA-N tipepidine Chemical compound C1N(C)CCCC1=C(C=1SC=CC=1)C1=CC=CS1 JWIXXNLOKOAAQT-UHFFFAOYSA-N 0.000 description 1
- 229960000896 tipepidine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、感冒用組成物に関
する。さらに詳しくは、風邪症候群による咳嗽症状に対
し鎮咳効果が改善された感冒用組成物に関する。TECHNICAL FIELD The present invention relates to a composition for colds. More specifically, the present invention relates to a composition for colds with an improved antitussive effect against cough symptoms caused by cold syndrome.
【０００２】[0002]
【従来の技術】一般に風邪症候群は大部分がウイルスを
原因とするものであり、諸々の全身または局所の症状を
伴い、３〜７日程度でほぼ治癒する呼吸器感染症であ
る。現在のところ、原因ウイルスが突然変異を起こしや
すいため、これらのウイルスに対する抗ウイルス剤の開
発が追いつかず、対症療法に頼らざるを得ないというの
が実状である。特に咳嗽症状は、主に風邪罹患期の後期
乃至末期に現れ、胸部筋肉等の負荷を伴うため体力の消
耗も大きく、長引くと風邪症状の遷延化を引き起こす。
したがって、咳嗽症状を如何に軽減・除去するかが治療
上のポイントの一つとなる。2. Description of the Related Art In general, the cold syndrome is mostly caused by a virus, and is a respiratory tract infection which is cured in about 3 to 7 days with various systemic or local symptoms. At present, the fact is that the causative viruses are susceptible to mutation, and the development of antiviral agents against these viruses has not been able to keep up and resort to symptomatic treatment. In particular, coughing symptoms mainly appear in the late to late stages of the cold illness, and the load on the chest muscles and the like cause a great loss of physical strength, and prolonged prolongation of the cold symptoms.
Therefore, how to reduce or eliminate cough symptoms is one of the therapeutic points.
【０００３】また近年は、風邪症候群とアレルギー素因
との関連性が注目されつつあり、気道過敏性の咳嗽症状
の発生頻度の抑制も治療上の新たな課題となりつつあ
る。[0003] In recent years, the relationship between the cold syndrome and allergic predisposition has been attracting attention, and suppression of the frequency of occurrence of airway irritable coughing has also become a new therapeutic issue.
【０００４】かかる状況下にあって、風邪症候群の咳嗽
症状に対応する風邪用咳止め薬としては、コデイン類を
はじめとする麻薬性のもの、中枢性の呼吸抑制作用を中
心とするものが汎用されているが、これらの薬物につい
ては、その有効性は実証されているものの、麻薬成分に
おいては習慣性をはじめ傾眠や幻覚等の、キサンチン類
にあっては習慣性、呼吸亢進、不眠、頻尿等の重篤な副
作用があることも確認されている。よって、その用法及
び用量は厳格に制限されている。このことは、広く生活
者に使用され、セルフメディケーションを目的とする一
般用医薬品の分野においては、その薬物の使用を阻害す
る要因として作用していた。Under these circumstances, as a cough medicine for colds corresponding to the cough symptom of the cold syndrome, narcotic drugs such as codeines and drugs mainly having a central respiratory depressant action are commonly used. Although the efficacy of these drugs has been demonstrated, the addictive nature of the narcotic component includes drowsiness and hallucinations. It has also been confirmed that there are serious side effects such as urine. Thus, its usage and dosage are strictly limited. This has been widely used by consumers and has acted as a factor inhibiting use of the drug in the field of over-the-counter drugs for the purpose of self-medication.
【０００５】[0005]
【発明が解決しようとする課題】したがって、本発明
は、副作用のない、風邪症候群による咳嗽症状に有効な
感冒用組成物を提供することを課題とする。SUMMARY OF THE INVENTION Accordingly, an object of the present invention is to provide a composition for colds which has no side effects and which is effective for cough symptoms caused by cold syndrome.
【０００６】[0006]
【課題を解決するための手段】そこで、本発明者らは、
ナプロキセン、ケトプロフェン等の非ステロイド性抗炎
症薬による咳嗽症状の軽減・除去作用を検討していたと
ころ、これら非ステロイド性抗炎症薬と交換神経興奮薬
とを配合することにより、鎮咳効果が増強され、かつ、
副作用も充分に許容範囲にあることを見い出し、本発明
を完成するに至った。すなわち、本発明は、（ａ）ナプ
ロキセン、ケトプロフェン、ロキソプロフェン、イソプ
ロピルアンチピリン、イブプロフェン、アセトアミノフ
ェン及びそれらの塩からなる群より選ばれる１種または
２種以上、並びに（ｂ）プソイドエフェドリンを含有す
ることを特徴とする感冒用組成物である。Means for Solving the Problems Accordingly, the present inventors have:
We were investigating the effects of reducing and eliminating cough symptoms with non-steroidal anti-inflammatory drugs such as naproxen and ketoprofen.By combining these non-steroidal anti-inflammatory drugs with sympathomimetics, the antitussive effect was enhanced. ,And,
The inventors have found that the side effects are also within an acceptable range, and have completed the present invention. That is, the present invention comprises (a) one or more selected from the group consisting of naproxen, ketoprofen, loxoprofen, isopropylantipyrine, ibuprofen, acetaminophen and salts thereof, and (b) pseudoephedrine. This is a characteristic composition for colds.
【０００７】本発明の（ａ）成分であるナプロキセン、
ケトプロフェン、ロキソプロフェン、イソプロピルアン
チピリン、イブプロフェン、アセトアミノフェンは、非
ステロイド性抗炎症薬の１種であって、これらは塩や水
和物であってもよい。また、１種を用いるだけでなく、
２種以上を組み合わせて用いても良い。The component (a) of the present invention, naproxen,
Ketoprofen, loxoprofen, isopropylantipyrine, ibuprofen, and acetaminophen are one type of nonsteroidal anti-inflammatory drugs, and these may be salts or hydrates. In addition to using one kind,
Two or more kinds may be used in combination.
【０００８】本発明の（ｂ）成分であるプセイドエフェ
ドリンは、交感神経興奮薬の１種であって、これも塩や
水和物であってもよい。（ａ）成分の成人に対する１日
当たりの配合量を例示すると次のようになる。ナプロキ
センでは通常１００〜７５０ｍｇであり、好ましくは１
５０〜６００ｍｇである。ケトプロフェンでは通常５０
〜３００ｍｇであり、好ましくは７５〜２００ｍｇであ
る。ロキソプロフェンでは１５〜２００ｍｇであり、好
ましくは６０〜１８０ｍｇである。イソプロピルアンチ
ピリンでは通常５０〜４５０ｍｇであり、好ましくは７
５〜３００ｍｇである。イブプロフェンでは通常５０〜
１２００ｍｇであり、好ましくは１００〜６００ｍｇで
ある。アセトアミノフェンでは通常１５０〜１５００ｍ
ｇであり、好ましくは３００〜９００ｍｇである。[0008] Pseudoephedrine, which is the component (b) of the present invention, is a kind of sympathomimetics and may be a salt or a hydrate. The following is an example of the daily amount of the component (a) for an adult. In naproxen, it is usually 100 to 750 mg, preferably 1 to 500 mg.
50-600 mg. Usually 50 for ketoprofen
３００300 mg, preferably 75-200 mg. For loxoprofen, the amount is 15 to 200 mg, preferably 60 to 180 mg. In the case of isopropylantipyrine, the amount is usually 50 to 450 mg, preferably 7 to 450 mg.
5 to 300 mg. For ibuprofen 50 ~
It is 1200 mg, preferably 100-600 mg. 150 ~ 1500m for acetaminophen
g, preferably 300 to 900 mg.
【０００９】（ｂ）成分であるプソイドエフェドリンの
配合量は（ａ）成分１質量部に対して通常０．０５質量
部以上、好ましくは０．２５〜１５質量部である。The amount of the pseudoephedrine as the component (b) is usually 0.05 parts by mass or more, preferably 0.25 to 15 parts by mass, per 1 part by mass of the component (a).
【００１０】[0010]
【発明の実施の形態】本発明の感冒用組成物は、（ａ）
成分に対して一定量の（ｂ）成分を配合することにより
調製できる。また、必要に応じて種々の薬剤を適宜に配
合し、咳嗽症状以外の他の風邪症状にも適用可能な薬剤
とすることもできる。BEST MODE FOR CARRYING OUT THE INVENTION The anti-cold composition of the present invention comprises (a)
It can be prepared by blending a fixed amount of the component (b) with the components. In addition, various drugs can be appropriately compounded as needed to make the drug applicable to cold symptoms other than cough symptoms.
【００１１】さらに本発明の感冒用組成物は、錠剤、顆
粒剤、細粒剤、散剤、カプセル剤、チュアブル剤、発泡
剤、ドロップ剤、口中瞬間溶解剤、ドライシロップ剤、
内服液剤、吸入剤、ストリーム剤等の各種製剤、投与形
態を適宜に選択することができる。The composition for colds of the present invention may further comprise tablets, granules, fine granules, powders, capsules, chewables, foaming agents, drops, instant dissolving agents in mouth, dry syrups,
Various preparations such as an oral solution, an inhalant, and a stream, and a dosage form can be appropriately selected.
【００１２】これらの製剤は、常法により調製すること
ができる。製剤の調製に使用する担体としては、乳糖、
デンプン、砂糖、マンニトール、結晶セルロースなどの
賦形剤、ヒドロキシプロピルセルロース、ヒドロキシプ
ロピルメチルセルロース、ゼラチン、ＰＶＰなどの結合
剤、カルボキシメチルセルロースカルシウム、低置換度
ヒドロキシプロピルセルロースなどの崩壊剤、ステアリ
ン酸マグネシウム、硬化ヒマシ油、タルクなどの滑沢剤
があり、この他必要に応じて溶解補助剤、緩衝剤、保存
剤、香料、色素、矯味剤などを使用することができる。These preparations can be prepared by a conventional method. Carriers used in the preparation of formulations include lactose,
Excipients such as starch, sugar, mannitol, crystalline cellulose, binders such as hydroxypropylcellulose, hydroxypropylmethylcellulose, gelatin, PVP, disintegrants such as carboxymethylcellulose calcium, low-substituted hydroxypropylcellulose, magnesium stearate, hardening Lubricants such as castor oil and talc can be used. In addition, if necessary, solubilizers, buffers, preservatives, flavors, dyes, flavoring agents, and the like can be used.
【００１３】また、内服液剤における製剤の調製に使用
する担体としては、ショ糖脂肪酸エステル類、ステアリ
ン酸ポリオキシル類、ポリオキシエチレンポリオキシプ
ロピレングリコール類、ポリオキシエチレンモノ脂肪酸
エステル類等の界面活性剤、合成ケイ酸アルミニウム、
ケイ酸マグネシウム、炭酸マグネシウム、酸化マグネシ
ウム、メタケイ酸アルミン酸マグネシウム等の増粘剤、
クエン酸緩衝液、リン酸緩衝液等の有機酸系・無機酸系
のｐＨ調整剤があり、この他必要に応じて溶解補助剤、
緩衝剤、保存剤、香料、甘味剤等を使用することができ
る。[0013] Carriers used for the preparation of a preparation in a liquid preparation for internal use include surfactants such as sucrose fatty acid esters, polyoxyl stearate, polyoxyethylene polyoxypropylene glycols and polyoxyethylene mono fatty acid esters. , Synthetic aluminum silicate,
Thickeners such as magnesium silicate, magnesium carbonate, magnesium oxide, magnesium metasilicate aluminate,
There are organic acid-based and inorganic acid-based pH adjusters such as citrate buffer, phosphate buffer, etc.
Buffers, preservatives, flavors, sweeteners and the like can be used.
【００１４】[0014]
【実施例】以下に実施例及び試験例を挙げ本発明をさら
に詳しく説明するが、本発明は下記の例に限定されるも
のではない。The present invention will be described in more detail with reference to examples and test examples below, but the present invention is not limited to the following examples.
【００１５】（実施例１）下記の各成分を秤量し充分混
合した後、混合粉体を打錠機（コレクト１９型：菊水製
作所社製）で打錠し、１錠重量２００ｍｇの錠剤を製し
た。 ナプロキセン ４５０ｇ リン酸ジヒドロコデイン ２４ｇ ｄｌ−マレイン酸クロルフェニラミン １２ｇ 塩酸プソイドエフェドリン ２４０ｇ 乳糖 ２５０ｇ 微結晶セルロース １８２ｇ ステアリン酸マグネシウム １２ｇExample 1 After weighing and thoroughly mixing the following components, the mixed powder was tableted with a tableting machine (Collect 19, manufactured by Kikusui Seisakusho) to produce a tablet weighing 200 mg per tablet. did. Naproxen 450 g Dihydrocodeine phosphate 24 g dl-Chlorpheniramine maleate 12 g Pseudoephedrine hydrochloride 240 g Lactose 250 g Microcrystalline cellulose 182 g Magnesium stearate 12 g
【００１６】（実施例２）下記の各成分を秤量し充分混
合した後、実施例１に準拠して１錠重量２００ｍｇの錠
剤を製した。 ケトプロフェン １００ｇ ｄ−マレイン酸クロルフェニラミン ６ｇ デキストロメトルファン ２４ｇ 塩酸プソイドエフェドリン １６０ｇ グアイフェネシン ２００ｇ 乳糖 ３４０ｇ 微結晶セルロース ３００ｇ ステアリン酸マグネシウム １５ｇ 硬化ヒマシ油 １５ｇExample 2 The following components were weighed and thoroughly mixed, and then a tablet weighing 200 mg per tablet was produced in accordance with Example 1. Ketoprofen 100 g d-Chlorpheniramine maleate 6 g dextromethorphan 24 g pseudoephedrine hydrochloride 160 g guaifenesin 200 g lactose 340 g microcrystalline cellulose 300 g magnesium stearate 15 g hardened castor oil 15 g
【００１７】（実施例３）下記の各成分を秤量し充分混
合した後、実施例１に準拠して１錠重量２３０ｍｇの錠
剤を製した。 ロキソプロフェンナトリウム ９０ｇ ｄ−マレイン酸クロルフェニラミン ６ｇ 塩酸プソイドエフェドリン ２００ｇ テオフィリン ４５０ｇ グアイフェネシン ２００ｇ 乳糖 ４００ｇ 微結晶セルロース ３７５ｇ ステアリン酸マグネシウム ２０ｇ 硬化ヒマシ油 １９ｇExample 3 The following components were weighed and thoroughly mixed, and a tablet weighing 230 mg was produced according to Example 1. Loxoprofen sodium 90 g d-Chlorpheniramine maleate 6 g pseudoephedrine hydrochloride 200 g theophylline 450 g guaifenesin 200 g lactose 400 g microcrystalline cellulose 375 g magnesium stearate 20 g hardened castor oil 19 g
【００１８】（実施例４）下記の各成分を秤量し充分混
合した後、実施例１に準拠し１て錠重量２５０ｍｇの錠
剤を製した。 イソプロピルアンチピリン １５０ｇ マレイン酸カルビノキサミン １２ｇ ノスカピン ４８ｇ グアヤコールスルホン酸カリウム １２５ｇ 塩酸プソイドエフェドリン ２４０ｇ プロキシフィリン ２１０ｇ 無水カフェイン ７５ｇ 乳糖 ３００ｇ 微結晶セルロース ２９０ｇ ステアリン酸マグネシウム ２０ｇ 硬化ヒマシ油 １７ｇExample 4 The following components were weighed and mixed well, and then a tablet having a tablet weight of 250 mg was produced according to Example 1. Isopropylantipyrine 150 g Carbinoxamine maleate 12 g Noscapine 48 g Potassium guaiacol sulfonate 125 g Pseudoephedrine hydrochloride 240 g Proxyfilin 210 g Anhydrous caffeine 75 g Lactose 300 g Microcrystalline cellulose 290 g Magnesium stearate 20 g Hardened castor oil 17 g
【００１９】（実施例５）下記の各成分を秤量し充分混
合した後、実施例１に準拠して１錠重量２５０ｍｇの錠
剤を製した。 イブプロフェン ４５０ｇ マレイン酸カルビノキサミン １２ｇ クエン酸チペピジン ４５ｇ グアヤコールスルホン酸カリウム １２５ｇ 塩酸プソイドエフェドリン １２０ｇ プロキシフィリン ２１０ｇ 無水カフェイン ７５ｇ ビタミンＢ１硝酸塩 ８ｇ 乳糖 ３００ｇ 微結晶セルロース ２９０ｇ ステアリン酸マグネシウム ２０ｇ 硬化ヒマシ油 １７ｇExample 5 The following components were weighed and mixed well, and then a tablet weighing 250 mg per tablet was produced in accordance with Example 1. Ibuprofen 450g maleic carbinoxamine 12g citric tipepidine 45g guaiacol sulfonic acid potassium 125g pseudoephedrine hydrochloride 120g proxy Villingen 210g anhydrous caffeine 75g Vitamin B 1 nitrate 8g Lactose 300g Microcrystalline cellulose 290g Magnesium stearate 20g hardened castor oil 17g
【００２０】（試験例）［配合製剤の咳嗽症状に対する
作用］ 体重３００〜４００ｇの Hartley系モルモットを用い、
室温２４±１℃の環境下で飼料及び飲料水を自由摂取さ
せて予備飼育後に実験に供した。(Test Example) [Effect of Combination Preparation on Cough Symptoms] Hartley guinea pigs weighing 300 to 400 g were used.
The animals were allowed to freely ingest feed and drinking water in an environment at room temperature of 24 ± 1 ° C., and were subjected to preliminary breeding before the experiment.
【００２１】無麻酔のモルモットを body plethysmogra
ph 内に入れた。body plethysmograph は、頭部と体部
の二つの透明なアクリル製の円筒状 box（約１．２Ｌ）
及び上下二つのゴム膜で覆ったアクリル製 neck restra
iner から構成されている。[0021] Non-anesthesia guinea pigs are treated with body plethysmogra
ph. The body plethysmograph is a transparent acrylic cylindrical box (about 1.2L) for the head and body
And acrylic neck restra covered with two rubber films
It consists of iner.
【００２２】Kohrogiらの方法（J.Clin.Invest.82,2063
-2068）に従い、容器の全面上部からcapsaicin を超音
波ネブライザー（ＴＵＲ−３２００，日本光電）により
２分間噴霧し（2.2mL/min）、咳の発現の有無、咳反射
の強さ及び頻度を調べた。咳嗽音をマイクロフォンで確
認するとともに、密閉した体部用 box の内圧の変化を
flow meter（ＭＥＰ−１１００，日本光電）を介してペ
ンレコーダー上に記録した。発生した咳嗽反応の１分間
の回数の抑制の有無を指標に評価した。なお、室温は２
５℃に設定した。The method of Kohrogi et al. (J. Clin. Invest. 82,2063)
According to -2068), capsaicin was sprayed from the top of the container with an ultrasonic nebulizer (TUR-3200, Nihon Kohden) for 2 minutes (2.2 mL / min), and the presence or absence of cough, cough reflex strength and frequency were examined. Was. While checking the coughing sound with a microphone, the change in the internal pressure of the closed body box
Recording was performed on a pen recorder via a flow meter (MEP-1100, Nihon Kohden). The evaluation was made based on the presence or absence of suppression of the number of 1-minute cough reactions that occurred. The room temperature is 2
Set to 5 ° C.
【００２３】比較した薬剤は、表１に示した処方を精製
水５０ｍＬに溶解したものを用いた。１群５匹で試験
し、各群とも capsaicin 噴霧３０分前に薬剤３ｍＬを
経口投与した。なお、コントロール群には、精製水３ｍ
Ｌを与えた。結果を表２に示す。As a comparison drug, a formulation shown in Table 1 dissolved in 50 mL of purified water was used. Each group consisted of 5 mice, and each group was orally administered 3 mL of the drug 30 minutes before spraying capsaicin. The control group had 3 m of purified water.
L was given. Table 2 shows the results.
【００２４】[0024]
【表１】試験薬の処方一覧 （５０ｍＬ中，単位ｍｇ） [Table 1] List of prescriptions for test drugs (unit: mg in 50 mL)
【００２５】[0025]
【表２】［咳嗽症状の回数とコントロール群（Ｈ群）に
対する抑制率］ [Table 2] [Number of cough symptoms and suppression rate for control group (H group)]
【００２６】Hartley系モルモットによる咳嗽反応に対
する抑制作用の程度はＡ〜Ｃ群が優っており、これらの
群の薬剤に優れた効果があることが確認された。The degree of the inhibitory effect of the Hartley guinea pig on the coughing reaction was superior in the groups A to C, and it was confirmed that the drugs in these groups had excellent effects.
【００２７】[0027]
【発明の効果】本発明により、風邪症候群による咳嗽症
状に有効な感冒薬を提供することが可能となった。Industrial Applicability According to the present invention, it has become possible to provide a common cold medicine effective for cough symptoms caused by cold syndrome.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 ＦＩ テーマコート゛(参考） Ａ６１Ｐ 11/14 Ａ６１Ｐ 11/14 (72)発明者 中神 浄二 東京都豊島区高田３丁目24番１号 大正製 薬株式会社内 (72)発明者 相川 勝義 東京都豊島区高田３丁目24番１号 大正製 薬株式会社内 (72)発明者 中川 泰緒 東京都豊島区高田３丁目24番１号 大正製 薬株式会社内 Ｆターム(参考） 4C086 AA01 AA02 BC36 MA02 MA03 MA04 MA09 MA10 NA05 ZA59 ZA62 ZC75 4C206 AA01 AA02 DA22 DA23 DA24 DA25 FA10 GA02 GA31 KA01 KA03 MA02 MA03 MA04 NA05 ZA59 ZA62 ZC75 ──────────────────────────────────────────────────の Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) A61P 11/14 A61P 11/14 (72) Inventor Joji Nakagami 3- 24-1, Takada, Toshima-ku, Tokyo No. Taisho Pharmaceutical Co., Ltd. (72) Katsuyoshi Aikawa, Inventor 3-24-1, Takada, Toshima-ku, Tokyo Taisho Pharmaceutical Co., Ltd. (72) Inventor Yasushi Nakagawa 3-24-1, Takada, Toshima-ku, Tokyo F term (reference) 4C086 AA01 AA02 BC36 MA02 MA03 MA04 MA09 MA10 NA05 ZA59 ZA62 ZC75 4C206 AA01 AA02 DA22 DA23 DA24 DA25 FA10 GA02 GA31 KA01 KA03 MA02 MA03 MA04 NA05 ZA59 ZA62 ZC75
Claims (1)
ロキソプロフェン、イソプロピルアンチピリン、イブプ
ロフェン、アセトアミノフェン及びそれらの塩からなる
群より選ばれる１種または２種以上、並びに（ｂ）プソ
イドエフェドリンを含有することを特徴とする感冒用組
成物。(A) naproxen, ketoprofen,
A composition for colds comprising one or more members selected from the group consisting of loxoprofen, isopropylantipyrine, ibuprofen, acetaminophen and salts thereof, and (b) pseudoephedrine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001120419A JP2002316927A (en) | 2001-04-19 | 2001-04-19 | Composition for common cold |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001120419A JP2002316927A (en) | 2001-04-19 | 2001-04-19 | Composition for common cold |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002316927A true JP2002316927A (en) | 2002-10-31 |
Family
ID=18970455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001120419A Withdrawn JP2002316927A (en) | 2001-04-19 | 2001-04-19 | Composition for common cold |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2002316927A (en) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006515299A (en) * | 2002-12-18 | 2006-05-25 | ワイス | Non-steroidal anti-inflammatory, decongestant and antihistamine composition |
| WO2007040188A1 (en) * | 2005-10-03 | 2007-04-12 | Sankyo Company, Limited | Medicinal composition for inhibiting the excessive formation of goblet cells |
| JP2011132226A (en) * | 2009-11-27 | 2011-07-07 | Kowa Co | Loxoprofen-containing medicinal composition and medicinal preparation containing the composition |
| JP2011132214A (en) * | 2009-09-28 | 2011-07-07 | Kowa Co | Loxoprofen-containing medicinal preparation |
| JP2011225514A (en) * | 2009-10-30 | 2011-11-10 | Kowa Co | Pharmaceutical composition containing loxoprofen or salt thereof |
| JP2011225527A (en) * | 2010-02-26 | 2011-11-10 | Kowa Co | Pharmaceutical composition containing loxoprofen or salt of the same |
| JP2012072106A (en) * | 2009-10-30 | 2012-04-12 | Kowa Co | Composition of loxoprofen-containing medicine |
| JP2012106977A (en) * | 2010-05-31 | 2012-06-07 | Kowa Co | Pharmaceutical composition containing loxoprofen |
| JP2012158589A (en) * | 2011-01-12 | 2012-08-23 | Kowa Co | Pharmaceutical composition containing loxoprofen or its salt |
| WO2012157752A1 (en) * | 2011-05-18 | 2012-11-22 | 興和株式会社 | Pharmaceutical composition containing loxoprofen |
| JP2014118348A (en) * | 2012-12-13 | 2014-06-30 | Shionogi & Co Ltd | Loxoprofen containing pharmaceutical composition |
| JP2014240369A (en) * | 2013-06-12 | 2014-12-25 | 興和株式会社 | Pharmaceutical composition comprising loxoprofen |
| JPWO2013018765A1 (en) * | 2011-07-29 | 2015-03-05 | 興和株式会社 | Pharmaceutical composition containing loxoprofen |
| JP2016106132A (en) * | 2010-02-26 | 2016-06-16 | 興和株式会社 | Loxoprofen-containing pharmaceutical preparation |
| JP2018076306A (en) * | 2016-10-31 | 2018-05-17 | エスエス製薬株式会社 | Cold remedy |
-
2001
- 2001-04-19 JP JP2001120419A patent/JP2002316927A/en not_active Withdrawn
Cited By (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7863287B2 (en) | 2002-12-18 | 2011-01-04 | Wyeth Llc | Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines |
| JP2006515299A (en) * | 2002-12-18 | 2006-05-25 | ワイス | Non-steroidal anti-inflammatory, decongestant and antihistamine composition |
| WO2007040188A1 (en) * | 2005-10-03 | 2007-04-12 | Sankyo Company, Limited | Medicinal composition for inhibiting the excessive formation of goblet cells |
| JP2011132214A (en) * | 2009-09-28 | 2011-07-07 | Kowa Co | Loxoprofen-containing medicinal preparation |
| JP2017132819A (en) * | 2009-10-30 | 2017-08-03 | 興和株式会社 | Pharmaceutical composition containing loxoprofen or salt thereof |
| JP2015166394A (en) * | 2009-10-30 | 2015-09-24 | 興和株式会社 | Pharmaceutical composition containing loxoprofen or salt thereof |
| JP2011225514A (en) * | 2009-10-30 | 2011-11-10 | Kowa Co | Pharmaceutical composition containing loxoprofen or salt thereof |
| JP2012072106A (en) * | 2009-10-30 | 2012-04-12 | Kowa Co | Composition of loxoprofen-containing medicine |
| JP2011132226A (en) * | 2009-11-27 | 2011-07-07 | Kowa Co | Loxoprofen-containing medicinal composition and medicinal preparation containing the composition |
| JP2015157866A (en) * | 2009-11-27 | 2015-09-03 | 興和株式会社 | Loxoprofen-containing composition |
| JP2016106132A (en) * | 2010-02-26 | 2016-06-16 | 興和株式会社 | Loxoprofen-containing pharmaceutical preparation |
| JP2011225527A (en) * | 2010-02-26 | 2011-11-10 | Kowa Co | Pharmaceutical composition containing loxoprofen or salt of the same |
| JP2015172093A (en) * | 2010-02-26 | 2015-10-01 | 興和株式会社 | Pharmaceutical composition containing loxoprofen or salt thereof |
| JP2012106977A (en) * | 2010-05-31 | 2012-06-07 | Kowa Co | Pharmaceutical composition containing loxoprofen |
| JP2016106138A (en) * | 2011-01-12 | 2016-06-16 | 興和株式会社 | Pharmaceutical composition comprising loxoprofen or salt thereof |
| JP2012158589A (en) * | 2011-01-12 | 2012-08-23 | Kowa Co | Pharmaceutical composition containing loxoprofen or its salt |
| JP2018135372A (en) * | 2011-01-12 | 2018-08-30 | 興和株式会社 | Pharmaceutical composition <3> containing loxoprofen or salt thereof |
| JPWO2012157752A1 (en) * | 2011-05-18 | 2014-07-31 | 興和株式会社 | Loxoprofen-containing pharmaceutical composition |
| WO2012157752A1 (en) * | 2011-05-18 | 2012-11-22 | 興和株式会社 | Pharmaceutical composition containing loxoprofen |
| JPWO2013018765A1 (en) * | 2011-07-29 | 2015-03-05 | 興和株式会社 | Pharmaceutical composition containing loxoprofen |
| JP2014118348A (en) * | 2012-12-13 | 2014-06-30 | Shionogi & Co Ltd | Loxoprofen containing pharmaceutical composition |
| JP2014240369A (en) * | 2013-06-12 | 2014-12-25 | 興和株式会社 | Pharmaceutical composition comprising loxoprofen |
| JP2018076306A (en) * | 2016-10-31 | 2018-05-17 | エスエス製薬株式会社 | Cold remedy |
| JP7163014B2 (en) | 2016-10-31 | 2022-10-31 | エスエス製薬株式会社 | cold medicine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002316927A (en) | Composition for common cold | |
| EP0717986B1 (en) | Rotor granulation and coating of acetaminophen, pseudoephedrine, chlorpheniramine, and, optionally, dextromethorphan | |
| JP2001172175A (en) | Composition for the cold | |
| JP2019019132A (en) | Stable pharmaceutical composition | |
| JP2007197357A (en) | Dry directly tableted quick-disintegrating tablet | |
| JPS6241646B2 (en) | ||
| JP2002332229A (en) | Composition for common cold | |
| JP2001151677A (en) | Composition for pharyngeal use | |
| KR20130141622A (en) | Antipyretic/analgesic composition | |
| JP2006096749A (en) | Medicine composition for common cold | |
| JP2002348240A (en) | Pharmaceutical composition | |
| JP2010241760A (en) | Tablet quickly disintegrable in oral cavity that has unpleasant taste reduced, and method for preparing the same | |
| JP2003012514A (en) | Medicament composition | |
| JP2002363072A (en) | Antitussive composition | |
| JP2001097856A (en) | Antitussive | |
| JP2003081821A (en) | Medicinal composition | |
| JP4519444B2 (en) | Orally disintegrating tablets | |
| JP2003104903A (en) | Antitussive composition | |
| JP2002212067A (en) | Composition for treating cold | |
| JP6073231B2 (en) | Stable pharmaceutical composition | |
| JP2002308761A (en) | Antitussive agent for common cold | |
| JP2000044463A (en) | Rapidly dissolvable tablet | |
| JP2000080034A (en) | Composition for cold | |
| JP4710240B2 (en) | Pharmaceutical composition | |
| JP2002348251A (en) | Pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20060324 |